22nd Century Group, Inc. (XXII)

22nd Century Group, Inc. (XXII) Consumer Business Overview

22nd Century Group, Inc. operates in the consumer defensive sector, focusing on agricultural biotechnology with an emphasis on tobacco harm reduction through very low nicotine (VLN) tobacco products. The company also develops hemp/cannabis plants for various applications, positioning it within both the tobacco and emerging cannabis markets.

What Is the Investment Thesis for XXII?

22nd Century Group's investment thesis centers on its potential to disrupt the tobacco industry with its very low nicotine (VLN) cigarettes. The company's VLN products, marketed under the VLN King and VLN Menthol King brands, offer a harm reduction alternative to traditional cigarettes. A key value driver is the increasing regulatory pressure to reduce nicotine levels in cigarettes, which could create a significant market opportunity for 22nd Century Group. The company's collaboration with Keygene N.V. to develop hemp/cannabis plants adds another layer of potential growth. However, the company's negative profit margin of -65.7% and gross margin of -34.3% present significant risks. Success depends on achieving profitability and scaling production to meet potential demand.

Based on FMP financials and quantitative analysis

XXII Key Highlights

• Market capitalization of $1.43M indicates a small-cap company with potential for growth but also higher risk.
• P/E ratio of -2.82 reflects the company's current lack of profitability.
• Negative profit margin of -65.7% highlights the company's challenges in achieving profitability.
• Negative gross margin of -34.3% indicates that the company's cost of goods sold exceeds its revenue.
• Beta of 0.99 suggests that the stock's volatility is similar to the overall market.

Who Are XXII's Competitors?

XXII is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XXII's Key Strengths?

• Proprietary technology for producing very low nicotine tobacco.
• First-mover advantage in the VLN cigarette market.
• Collaboration with Keygene N.V. for hemp/cannabis development.
• Focus on tobacco harm reduction.

What Are XXII's Weaknesses?

• Negative profit margin and gross margin.
• Limited market share in the tobacco industry.
• Dependence on regulatory approvals for VLN products.
• Small market capitalization.

What Could Drive XXII Stock Higher?

• Potential regulatory mandates for reduced nicotine levels in cigarettes could drive demand for VLN products.
• Clinical studies demonstrating the health benefits of VLN cigarettes could increase consumer adoption.
• Expansion of distribution channels for VLN cigarettes could increase sales and market share.
• Potential regulatory approvals for novel cannabis products could generate new revenue streams.

What Are the Key Risks for XXII?

• Financial-distress signal — its Altman Z-Score of -18.98 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-25.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory setbacks or delays could hinder the commercialization of VLN tobacco and cannabis products.
• Competition from established tobacco companies could limit market share gains.
• Changing consumer preferences could reduce demand for VLN cigarettes.
• Economic downturn could negatively impact consumer spending on tobacco and cannabis products.
• Inability to achieve profitability could threaten the company's long-term viability.

What Are the Growth Opportunities for XXII?

• Regulatory tailwinds: The increasing regulatory pressure to reduce nicotine levels in cigarettes represents a significant growth opportunity for 22nd Century Group. If regulations mandate lower nicotine levels, the demand for the company's VLN products could increase substantially. The timeline for such regulatory changes is uncertain, but the trend is clear. This could lead to a significant increase in revenue and market share for 22nd Century Group.
• Expansion into the cannabis market: 22nd Century Group's collaboration with Keygene N.V. to develop hemp/cannabis plants with exceptional cannabinoid profiles offers a growth opportunity in the rapidly expanding cannabis market. The company can leverage its expertise in plant biotechnology to develop and commercialize novel cannabis products for medical, therapeutic, and agricultural uses. The timeline for this growth opportunity depends on regulatory approvals and market acceptance of cannabis products.
• Partnerships and collaborations: Forming strategic partnerships and collaborations with other companies in the tobacco and cannabis industries could accelerate 22nd Century Group's growth. These partnerships could provide access to new markets, technologies, and distribution channels. The company can also collaborate with research institutions to further develop its VLN tobacco and cannabis products. The timeline for these partnerships is uncertain, but they could significantly enhance the company's growth prospects.
• Product innovation: Investing in research and development to further improve its VLN tobacco and cannabis products is crucial for 22nd Century Group's long-term growth. The company can develop new VLN cigarette brands, explore alternative nicotine delivery systems, and create novel cannabis products with unique cannabinoid profiles. The timeline for product innovation depends on the company's R&D capabilities and regulatory approvals.
• International expansion: Expanding its sales and marketing efforts to international markets represents a significant growth opportunity for 22nd Century Group. The company can target countries with high smoking rates and increasing regulatory pressure to reduce nicotine levels. International expansion would require significant investment in marketing and distribution, but it could substantially increase the company's revenue and market share. The timeline for international expansion depends on regulatory approvals and market conditions in each target country.

What Opportunities Does XXII Have?

• Increasing regulatory pressure to reduce nicotine levels in cigarettes.
• Growing demand for harm reduction tobacco products.
• Expansion into the cannabis market.
• Strategic partnerships and collaborations.

What Threats Does XXII Face?

• Competition from established tobacco companies.
• Regulatory hurdles and uncertainty.
• Changing consumer preferences.
• Economic downturn.

What Are XXII's Competitive Advantages?

• Proprietary technology for producing very low nicotine tobacco.
• Intellectual property protection for VLN tobacco and cannabis products.
• First-mover advantage in the VLN cigarette market.
• Established relationships with research institutions and industry partners.

What Does XXII Do?

22nd Century Group, Inc., founded in 1998 and headquartered in Buffalo, New York, is an agricultural biotechnology company dedicated to reducing the harm caused by tobacco. The company's primary focus is on developing and commercializing very low nicotine content (VLN) tobacco and cigarette products, marketed under the VLN King and VLN Menthol King brands. These products are designed to help smokers reduce their nicotine consumption and potentially quit smoking altogether. In addition to its VLN tobacco products, 22nd Century Group also produces SPECTRUM research cigarettes, which are used in independent clinical studies to evaluate the effects of reduced nicotine tobacco. The company collaborates with Keygene N.V. to develop hemp/cannabis plants with exceptional cannabinoid profiles and other superior agronomic traits, targeting medical, therapeutic, and agricultural uses. This collaboration diversifies 22nd Century Group's portfolio beyond tobacco and into the rapidly growing cannabis market. The company's mission is to enhance health and wellness through plant science, serving both the life science and consumer products industries. Despite its innovative products, 22nd Century Group faces challenges in a highly regulated and competitive market.

What Products and Services Does XXII Offer?

• Develops very low nicotine content (VLN) tobacco products.
• Markets VLN cigarettes under the VLN King and VLN Menthol King brands.
• Produces SPECTRUM research cigarettes for independent clinical studies.
• Collaborates with Keygene N.V. to develop hemp/cannabis plants.
• Focuses on tobacco harm reduction through reduced nicotine tobacco.
• Enhances health and wellness through plant science.

How Does XXII Make Money?

• Generates revenue from the sale of VLN cigarettes.
• Earns revenue from the sale of SPECTRUM research cigarettes.
• Potentially generates revenue from the commercialization of hemp/cannabis plants.
• Focuses on licensing and partnerships for technology and product distribution.

What Industry Does XXII Operate In?

22nd Century Group operates within the tobacco industry, which is facing increasing regulatory pressure to reduce nicotine levels in cigarettes. This trend creates a potential market opportunity for companies like 22nd Century Group that offer very low nicotine (VLN) products. The company also participates in the emerging cannabis market through its collaboration with Keygene N.V. Competitors include traditional tobacco companies and other biotechnology firms developing novel tobacco and cannabis products. The industry is characterized by high barriers to entry due to regulatory requirements and established brand loyalty.

Who Are XXII's Key Customers?

• Smokers seeking to reduce their nicotine consumption.
• Researchers conducting clinical studies on reduced nicotine tobacco.
• Potential consumers of hemp/cannabis products for medical, therapeutic, and agricultural uses.
• Tobacco companies seeking to license VLN technology.

Net buyingInsider Activity

The most recent 12 insider filings for 22nd Century Group, Inc. break down as 0 sales and 12 purchases. On net that is roughly 670K shares acquired (about $638K) — insiders putting money in tends to read as conviction.

FY2026 estForward Outlook

Wall Street analysts project 22nd Century Group, Inc. revenue of about $32.5M for fiscal 2026, with EPS near $-18.00.

F-Score 2/9Financial Health

22nd Century Group, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -18.98 places it in the distress zone, a signal of elevated financial risk.

ROE -25%Key Financial Metrics

Return on equity for 22nd Century Group, Inc. stands at -25.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.2%, showing how much profit it generates from its asset base. A current ratio of 2.67 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -167.0%, the inverse of the P/E and a quick read on earnings relative to price.

22nd Century Group, Inc. (XXII) Valuation Context

Valued at $1.43M, XXII is classified as a micro-cap stock. Relative to its peer group, XXII's quantitative score of 18/100 is below the peer average of 50/100.

XXII Financials

XXII Latest News

XXII Analyst Consensus

XXII MoonshotScore

Latest 22nd Century Group, Inc. Analysis

XXII Consumer Defensive Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources